| 臺大學術典藏 |
2021-09-01T01:53:52Z |
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells
|
Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; ANN-LII CHENG; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:47Z |
Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3
|
Huang C.-Y.; Lin C.-S.; Tai W.-T.; Hsieh C.-Y.; Shiau C.-W.; ANN-LII CHENG; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2017) 66(3) (666�V668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-24T06:05:06Z |
SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells
|
CHEN-TI WANG; Lin C.-S.; Shiau C.-W.; Chu P.-Y.; Hsiao C.-C.; Chiang Y.-L.; Tai W.-T.; Chen K.-F. |
| 臺大學術典藏 |
2021-07-06T02:04:11Z |
STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma
|
Tai W.-T.; Chu P.-Y.; Shiau C.-W.; Chen Y.-L.; Li Y.-S.; Hung M.-H.; Chen L.-J.; PEI-LUNG CHEN; Su J.-C.; Lin P.-Y.; Yu H.-C.; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:40Z |
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
|
Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; Cheng A.-L.; PEI-JER CHEN; Shiau C.-W. |
| 臺大學術典藏 |
2021-07-03T03:34:40Z |
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
|
Chen K.-F.; Tai W.-T.; Liu T.-H.; Huang H.-P.; Lin Y.-C.; Shiau C.-W.; Li P.-K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:38Z |
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
|
Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; Hsu C.-H.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:35Z |
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
|
Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:30Z |
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
|
Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN; Kim I.; Shiau C.-W. |
| 臺大學術典藏 |
2021-07-03T03:34:29Z |
Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists
|
Su J.-C.; Chen K.-F.; Chen W.-L.; Liu C.-Y.; Huang J.-W.; Tai W.-T.; PEI-JER CHEN; Kim I.; Shiau C.-W. |
| 臺大學術典藏 |
2021-07-03T03:34:27Z |
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3
|
Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:26Z |
Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
|
Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:25Z |
Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells
|
Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:23Z |
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells
|
Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; Cheng A.-L.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:22Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:13Z |
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model
|
Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:12Z |
Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma
|
Tai W.-T.; Shiau C.-W.; PEI-JER CHEN; Chu P.-Y.; Huang H.-P.; Liu C.-Y.; Huang J.-W.; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:33:59Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; PEI-JER CHEN; Chen K.-F.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:33:49Z |
Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))
|
Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:33:47Z |
Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))
|
Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:33:43Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; PEI-JER CHEN; Chen D.-S.; Chen K.-F.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:42Z |
Corrigendum to “Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity” (Eur. J. Med. Chem. (2012) 55 (220–227)(S0223523412004497)(10.1016/j.ejmech.2012.07.023))
|
Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN; Kim I.; Shiau C.-W. |
